(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion, granting Lilly access to its AI-driven platform to discover and develop ...
Hosted on MSN
Eli Lilly (LLY) Signs $1.3 Billion Deal with Superluminal to Discover Future Drugs Using AI
Eli Lilly (LLY) has signed a $1.3 billion deal with privately held biotechnology firm Superluminal Medicines that will see the two companies employ artificial intelligence (AI) for future drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback